Artelo Biosciences, Inc.
ARTL
$7.16
-$0.15-2.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -33.53% | 3.14% | -35.79% | 37.22% | -233.75% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -14.46% | 53.70% | -- | -- | -- |
| Total Other Non-Cash Items | 356.83% | 130.19% | -20.50% | 13.64% | 14.29% |
| Change in Net Operating Assets | 40.99% | -133.16% | 333.74% | -44.44% | 417.50% |
| Cash from Operations | 16.78% | -580.54% | 67.81% | 37.79% | -229.95% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 175.20% | -- | -- | -- | -88.24% |
| Cash from Investing | 175.20% | -- | -- | -- | -88.24% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -48.90% | 219.18% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -53.34% | 89.65% | -- | -- | -- |
| Foreign Exchange rate Adjustments | 90.48% | -333.33% | 260.00% | 155.56% | -325.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -223.70% | -126.21% | 182.91% | 21.15% | -158.08% |